An antibody–drug conjugate (ADC) targeting HER2; binds HER2 on tumor cells (including HER2-low), is internalized, and releases a cytotoxic payload to kill cancer cells and disrupt HER2-driven signaling.
HER2-targeted antibody–drug conjugate; the trastuzumab-based antibody binds HER2 (including HER2-low) on tumor cells, is internalized, and a cleavable linker releases a camptothecin/topoisomerase I–inhibiting payload that induces DNA damage, inhibits replication, and triggers apoptosis, while also disrupting HER2-driven signaling.
HER2-targeted ADC binds HER2, is internalized, and releases a camptothecin/topoisomerase I–inhibiting payload that causes DNA damage, blocks replication, and induces apoptosis in the HER2-expressing cells.
Humanized anti-EGFR IgG1 monoclonal antibody; blocks EGFR ligand binding, inhibiting RAS/RAF/MEK/ERK and PI3K/AKT signaling and can trigger ADCC.
Humanized IgG1 monoclonal antibody against EGFR that blocks ligand binding and receptor activation, suppressing downstream RAS/RAF/MEK/ERK and PI3K/AKT signaling to inhibit tumor cell growth; its Fc domain can also mediate ADCC.
Anti-EGFR IgG1 binds EGFR on target cells and its Fc engages Fcγ receptors on NK cells/macrophages to trigger ADCC; blockade of EGFR signaling also reduces survival and can induce apoptosis.
A CDH6-targeting antibody–drug conjugate (DAR-8) administered IV every 21 days; binds Cadherin-6 on tumor cells, is internalized, and releases a cytotoxic payload to kill CDH6-expressing cancer cells.
HS-20124 is a CDH6-targeting monoclonal antibody–drug conjugate that binds Cadherin-6 on tumor cells, is internalized, and releases a cytotoxic payload intracellularly, leading to targeted killing of CDH6-expressing cancer cells.
The ADC binds Cadherin-6 on target cells, is internalized, and releases a cytotoxic payload inside the cell, directly killing Cadherin-6-expressing cells.
Bispecific IgG1 monoclonal antibody targeting EGFR and MET; blocks signaling, promotes receptor downregulation, and mediates immune killing via ADCC/CDC.
Bispecific IgG1 monoclonal antibody that binds EGFR and MET (wild-type and select mutants), blocks receptor phosphorylation and downstream signaling, promotes receptor internalization/degradation, and induces Fc-mediated ADCC/CDC to inhibit tumor cell growth.
Amivantamab binds EGFR on target cells and engages immune effectors via its IgG1 Fc to induce ADCC and complement-mediated lysis (CDC); receptor blockade/internalization may contribute to cell death.
Bispecific IgG1 monoclonal antibody targeting EGFR and MET; blocks signaling, promotes receptor downregulation, and mediates immune killing via ADCC/CDC.
Bispecific IgG1 monoclonal antibody that binds EGFR and MET (wild-type and select mutants), blocks receptor phosphorylation and downstream signaling, promotes receptor internalization/degradation, and induces Fc-mediated ADCC/CDC to inhibit tumor cell growth.
Amivantamab binds MET on target cells and engages Fc receptors to trigger ADCC and complement-dependent cytotoxicity (CDC), with additional receptor downregulation/signaling blockade.